Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization EBIAT Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Shares Issued Shares Outstanding Shares Outstanding

Ratios

Crescent Biopharma (CBIO) Shares Issued (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Shares Issued for 10 consecutive years, with -$5000.0 as the latest value for Q4 2025.

For Q4 2025, Shares Issued changed N/A year-over-year to -$5000.0; the TTM value through Jun 2025 reached $9898.0, changed N/A, while the annual FY2024 figure was $5398.0, 99.98% down from the prior year.
Shares Issued hit -$5000.0 in Q4 2025 for Crescent Biopharma, down from $5000.0 in the prior quarter.
Across five years, Shares Issued topped out at $28.7 million in Q1 2023 and bottomed at -$28.7 million in Q2 2023.
Average Shares Issued over 4 years is $3.2 million, with a median of $4898.0 recorded in 2024.
Year-over-year, Shares Issued crashed 99.98% in 2024 and then grew 2.08% in 2025.
Crescent Biopharma's Shares Issued stood at -$9.5 million in 2021, then surged by 400.52% to $28.7 million in 2023, then tumbled by 99.98% to $4898.0 in 2024, then tumbled by 202.08% to -$5000.0 in 2025.
According to Business Quant data, Shares Issued over the past three periods came in at -$5000.0, $5000.0, and $4898.0 for Q4 2025, Q1 2025, and Q1 2024 respectively.